Logo of the .Logo of the . (Photo credit: Wikipedia)

FDA Issues Warning On Revlimid-Cancer Link in Multiple Myeloma – Topix.

The US Food & Drug Administration is issuing a warning to multiple myeloma patients and health care providers about what it sees as a link between multiple myeloma patients, maintenance use of Revlimid, and the incidence of secondary cancer development.

After reviewing three separate clinical trials involving patients newly diagnosed with multiple myeloma who underwent chemotherapy and a stem cell transplantation followed by maintenance therapy with Revlimid, the FDA says it sees a three-fold increased risk among those patients of developing a second, primary cancerRead More

Related articles

Enhanced by Zemanta